3种方案治疗重症ITP短期疗效和成本-效果分析  

The short-term efficacy and cost-effectiveness analysis on 3 regimens for treating severe idiopathic thrombocytopenic purpura

作　　者：林晓骥[1] 姚荣欣[1] 何牧卿[1] 郭文坚[1] 朱宝玲[1] 

机构地区：[1]温州医学院附属第二医院血液科,325000

出　　处：《实用医学杂志》2013年第2期214-216,共3页The Journal of Practical Medicine

基　　金：温州市科技局基金资助项目(编号:H20100059)

摘　　要：目的:评价3种方案治疗重症ITP的治疗效果,探讨3种方案治疗ITP的药物经济学效果,为治疗ITP提供参考。方法:对76例ITP患者进行回顾性分析,分为IVIG组、rhIL-11+DXM组及DXM组,观察3组治疗方案的短期疗效,运用成本效果分析对3种治疗方案进行评价。结果:IVIG组、rhIL-11+DXM组及DXM组第7天总有效率分别为95.23%、91.30%和84.37%,P>0.05;IVIG组和rhIL-11+DXM组在治疗第5天时血小板计数及有效率均高于DXM组,P<0.05;IVIG组血小板上升至30×109/L所需时间明显短于rhIL-11+DXM组和DXM组,而rhIL-11+DXM组所需时间小于DXM组,P<0.05;IVIG组、rhIL-11+DXM组和DXM组C/E分别为220.18、61.95和41.05;以DXM组为参照,IVIG组和rhIL-11+DXM组ΔC/ΔE分别为1450.58和297.58。结论:3组在治疗重症ITP短期总有效率高。IVIG组提升血小板计数最迅速,但价格最昂贵,DXM组治疗最经济,rhIL-11+DXM组介于两者之间。Objective To assess the effects of 3 regimens of therapy on patients with severe idiopathic thrombocytopenic purpura （ITP）, and to analyze tho cost-effectiveness ratio. Methods 76 cases with severe ITP were divided into 3 groups： IVIG group, rhIL-11＋DXM group and DXM group. The short-term response of the 3 groups was observed, and then the cost-effectiveness analysis was made. Results The total effective rates at day 7 in IVIG group, rhIL-II＋DXM group and DXM group were 95.23%, 91.30% and 84.37%, respectively （P 〉 0.05）. The platelet counts and effective rates at day 5 in IVIG group and rhIL-11 ＋DXM were greater than those in DXM group （P 〈 0.05）. The duration of platelet ascending to 30 × 109/L in IVIG group was the lest, and that in DXM group was the highest （each P 〈 0.05）. The C/Es were 220.18, 61.95 and 41.05 in IVIG group, rhIL-11＋DXM group and DXM group, respectively. With DXM group as the reference, AC/AE in IVIG group and rhIL-11 ＋DXM group were 1 450.58 and 297.58, respectively. Conclusion The 3 regimens of therapy for ITP were similarly effective. IVIG was the fastest in ascending platelet and was the most expensive; while DXM was the most economical solution. The cost and effect in rhIL-11 ＋DXM group were the media.

关 键 词：免疫性血小板减少症 丙种球蛋白 基因重组人白介素-11 地塞米松 成本效果分析 

分 类 号：R558.2[医药卫生—血液循环系统疾病]